130 related articles for article (PubMed ID: 2697597)
41. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
42. [Role of the assay of serum beta 2 microglobulin in the clinical evaluation of myeloma].
Bataille R; Grenier J
Presse Med; 1986 Oct; 15(34):1723-5. PubMed ID: 2947132
[TBL] [Abstract][Full Text] [Related]
43. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
44. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates.
Stäbler A; Baur A; Bartl R; Munker R; Lamerz R; Reiser MF
AJR Am J Roentgenol; 1996 Oct; 167(4):1029-36. PubMed ID: 8819407
[TBL] [Abstract][Full Text] [Related]
45. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma.
Alexandrakis MG; Passam FH; Kyriakou DS; Dambaki K; Niniraki M; Stathopoulos E
Am J Clin Oncol; 2004 Feb; 27(1):8-13. PubMed ID: 14758126
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.
Durie BG; Stock-Novack D; Salmon SE; Finley P; Beckord J; Crowley J; Coltman CA
Blood; 1990 Feb; 75(4):823-30. PubMed ID: 2405920
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
Scarffe JH; Anderson H; Palmer MK; Crowther D
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups.
Peest D; Coldewey R; Deicher H; Sailer M; Vykoupil C; Leo R; Georgii A; Karow J; Hoeppner E; Diehl V
Eur J Cancer; 1993; 29A(7):978-83. PubMed ID: 8499152
[TBL] [Abstract][Full Text] [Related]
49. Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
Diem H; Fateh-Moghadam A; Lamerz R
Clin Investig; 1993 Nov; 71(11):918-23. PubMed ID: 8312685
[TBL] [Abstract][Full Text] [Related]
50. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
51. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
52. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
53. Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter.
Boccadoro M; Omedè P; Frieri R; Battaglio S; Gallone G; Massaia M; Redoglia V; Pileri A
Acta Haematol; 1989; 82(3):122-5. PubMed ID: 2510433
[TBL] [Abstract][Full Text] [Related]
54. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma.
Sezer O; Niemöller K; Jakob C; Zavrski I; Heider U; Eucker J; Kaufmann O; Possinger K
Ann Hematol; 2001 Oct; 80(10):598-601. PubMed ID: 11732871
[TBL] [Abstract][Full Text] [Related]
55. [Prognostic significance of beta-2-microglobulin in multiple myeloma].
Podol'tseva EI; Morozova EV; Almazov VA
Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455
[TBL] [Abstract][Full Text] [Related]
56. Prognosis of asymptomatic multiple myeloma.
Alexanian R; Barlogie B; Dixon D
Arch Intern Med; 1988 Sep; 148(9):1963-5. PubMed ID: 2458080
[TBL] [Abstract][Full Text] [Related]
57. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
Pasqualetti P; Colantonio D; Casale R; Di Lauro G; Collacciani A; Festuccia V; Trotta A; Natali G
Ann Ital Med Int; 1990; 5(3 Pt 1):195-204. PubMed ID: 2288822
[TBL] [Abstract][Full Text] [Related]
58. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Lust JA; Greipp PR; Therneau TM; Kyle RA; Litzow MR; Gertz MA
Bone Marrow Transplant; 1999 Jun; 23(12):1261-6. PubMed ID: 10414913
[TBL] [Abstract][Full Text] [Related]
59. Prognostic factors in multiple myeloma: a new staging system based on clinical and morphological features.
Pasqualetti P; Casale R; Collacciani A; Colantonio D
Eur J Cancer; 1991; 27(9):1123-6. PubMed ID: 1835621
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
